期刊
PSYCHO-ONCOLOGY
卷 31, 期 8, 页码 1294-1301出版社
WILEY
DOI: 10.1002/pon.5928
关键词
cancer; cancer-related cognitive impairment; cognition; concentration; memory; neuropsychology; psycho-oncology; screening
Cognitive symptoms are frequently reported by cancer patients, but there is a lack of guidance on when self-reported cognitive symptoms should be followed up. This study aimed to establish cut-off scores for identifying patients with perceived low cognitive functioning using widely used self-report measures and a new cognitive change score. The results showed that a single item question on cognitive change has acceptable discrimination between patients with self-reported normal and low cognitive functioning when compared to other comprehensive self-report measures of cognitive symptoms.
Objectives Cognitive symptoms are commonly reported among cancer patients and survivors, yet guidance on when self-reported cognitive symptoms warrant follow-up is lacking. We sought to establish cut-off scores for identifying patients with perceived low cognitive functioning on widely used self-report measures of cognition and a novel single item Cognitive Change Score. Methods Adult patients diagnosed with invasive cancer who had completed at least one cycle of chemotherapy completed a questionnaire containing the EORTC-Cognitive Function (CF) subscale, Functional Assessment of Cancer Therapy-Cognitive Function (FACT-COG) Perceived Cognitive Impairment (PCI) and our Cognitive Change Score (CCS). We used receiver operating characteristic analyses to establish the discriminative ability of these measures against the Patient's Assessment of Own Functioning Inventory (PAOFI) as our reference standard. We chose cut-off scores on each measure that maximised both sensitivity and specificity for identifying patients with self-reported low CF. Results We recruited 294 participants (55.8% women, mean age 56.6 years) with mixed cancer diagnoses (25.5 months since diagnosis). On the CCS, 77.6% reported some cognitive change since starting chemotherapy. On the PAOFI 36% had low CF. The following cut-off scores identified cases of low CF: >= 28.5 on the CCS (75.5% sensitivity, 67.6% specificity); <= 75.0 on the European Organisation for Research and Treatment of Cancer, QLQ-C30 Cognitive Functioning scale (90.9% sensitivity, 57.1% specificity); <= 55.1 on the FACT-COG PCI-18 (84.8% sensitivity, 76.2% specificity), and <= 59.5 on the FACT-COG PCI-20 (78.8% sensitivity, 84.1% specificity). Conclusions We found a single item question asking about cognitive change has acceptable discrimination between patients with self-reported normal and low CF when compared to other more comprehensive self-report measures of cognitive symptoms. Further validation work is required.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据